Sodium-Glucose Cotransporter-2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Discontinuation in Patients with CKD

Overview

Journal J Am Soc Nephrol

Specialty Nephrology

Date 2024 Aug 26

PMID 39186372

Authors

L Parker Gregg

Peter A Richardson

Vijay Nambi

Laura A Petersen

Michael E Matheny

Salim S Virani

Sankar D Navaneethan

Affiliations

Soon will be listed here.

References

Wiviott S, Raz I, Bonaca M, Mosenzon O, Kato E, Cahn A . Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2018; 380(4):347-357. DOI: 10.1056/NEJMoa1812389. View

Heerspink H, Stefansson B, Correa-Rotter R, Chertow G, Greene T, Hou F . Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020; 383(15):1436-1446. DOI: 10.1056/NEJMoa2024816. View

James P, Oparil S, Carter B, Cushman W, Dennison-Himmelfarb C, Handler J . 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2013; 311(5):507-20. DOI: 10.1001/jama.2013.284427. View

Deyo R, Cherkin D, Ciol M . Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992; 45(6):613-9. DOI: 10.1016/0895-4356(92)90133-8. View

Inker L, Eneanya N, Coresh J, Tighiouart H, Wang D, Sang Y . New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med. 2021; 385(19):1737-1749. PMC: 8822996. DOI: 10.1056/NEJMoa2102953. View

Neal B, Perkovic V, Mahaffey K, de Zeeuw D, Fulcher G, Erondu N . Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017; 377(7):644-657. DOI: 10.1056/NEJMoa1611925. View

Herrington W, Staplin N, Wanner C, Green J, Hauske S, Emberson J . Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2022; 388(2):117-127. PMC: 7614055. DOI: 10.1056/NEJMoa2204233. View

Gregg L, Worsley M, Ramsey D, Segar M, Matheny M, Virani S . Racial and Ethnic Disparities and Facility-Level Variation in GLP-1 RA Prescription among US Veterans with CKD. Clin J Am Soc Nephrol. 2023; 18(11):1479-1482. PMC: 10637447. DOI: 10.2215/CJN.0000000000000266. View

. KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney Int. 2022; 102(5S):S1-S127. DOI: 10.1016/j.kint.2022.06.008. View

10.

Kristensen S, Rorth R, Jhund P, Docherty K, Sattar N, Preiss D . Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol. 2019; 7(10):776-785. DOI: 10.1016/S2213-8587(19)30249-9. View

11.

Gerstein H, Colhoun H, Dagenais G, Diaz R, Lakshmanan M, Pais P . Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019; 394(10193):121-130. DOI: 10.1016/S0140-6736(19)31149-3. View

12.

Pfeffer M, Claggett B, Diaz R, Dickstein K, Gerstein H, Kober L . Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. N Engl J Med. 2015; 373(23):2247-57. DOI: 10.1056/NEJMoa1509225. View

13.

Heerspink H, Oshima M, Zhang H, Li J, Agarwal R, Capuano G . Canagliflozin and Kidney-Related Adverse Events in Type 2 Diabetes and CKD: Findings From the Randomized CREDENCE Trial. Am J Kidney Dis. 2021; 79(2):244-256.e1. DOI: 10.1053/j.ajkd.2021.05.005. View

14.

Limonte C, Hall Y, Trikudanathan S, Tuttle K, Hirsch I, de Boer I . Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes. J Diabetes Complications. 2022; 36(6):108204. DOI: 10.1016/j.jdiacomp.2022.108204. View

15.

Lamprea-Montealegre J, Madden E, Tummalapalli S, Peralta C, Neilands T, Garcia P . Association of Race and Ethnicity With Prescription of SGLT2 Inhibitors and GLP1 Receptor Agonists Among Patients With Type 2 Diabetes in the Veterans Health Administration System. JAMA. 2022; 328(9):861-871. PMC: 9449794. DOI: 10.1001/jama.2022.13885. View

16.

Marso S, Bain S, Consoli A, Eliaschewitz F, Jodar E, Leiter L . Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. N Engl J Med. 2016; 375(19):1834-1844. DOI: 10.1056/NEJMoa1607141. View

17.

Perkovic V, Jardine M, Neal B, Bompoint S, Heerspink H, Charytan D . Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019; 380(24):2295-2306. DOI: 10.1056/NEJMoa1811744. View

18.

Zinman B, Wanner C, Lachin J, Fitchett D, Bluhmki E, Hantel S . Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015; 373(22):2117-28. DOI: 10.1056/NEJMoa1504720. View

19.

Navaneethan S, Akeroyd J, Ramsey D, Ahmed S, Mishra S, Petersen L . Facility-Level Variations in Kidney Disease Care among Veterans with Diabetes and CKD. Clin J Am Soc Nephrol. 2018; 13(12):1842-1850. PMC: 6302320. DOI: 10.2215/CJN.03830318. View

20.

Walther C, Winkelmayer W, Richardson P, Virani S, Navaneethan S . Renin-angiotensin system blocker discontinuation and adverse outcomes in chronic kidney disease. Nephrol Dial Transplant. 2020; 36(10):1893-1899. PMC: 8633426. DOI: 10.1093/ndt/gfaa300. View